Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/17 | $32,000,000 | Series A |
Alexandria Real Estate Equities Cobro Ventures  Emigrant Capital Korea Investment Partners Morningside Venture | undisclosed |
